Kentucky’s Medical Cannabis Program: What Patients Need to Know
Kentucky’s medical cannabis program is now operating under a framework created by Senate Bill 47, which Gov. Andy Beshear signed into law on March 31, 2023. Medical cannabis became legal for qualifying patients on January 1, 2025. The program is administered by the Cabinet for Health and Family Services through the Office of Medical Cannabis.
The law creates a regulated system for patients, medical cannabis practitioners, caregivers and licensed cannabis businesses. It does not make cannabis legal for general recreational use, and Kentucky’s program does not eliminate the conflict between state authorization and federal law. The federal Drug Enforcement Administration continues to list marijuana as a Schedule I controlled substance, even as federal rescheduling proceedings continue.
Who can qualify?
Under Kentucky’s original statutory framework, patients may qualify if they have one of several conditions or symptoms, including:
- Any type or form of cancer;
- Chronic, severe, intractable or debilitating pain;
- Epilepsy or another intractable seizure disorder;
- Multiple sclerosis, muscle spasms or spasticity;
- Chronic nausea or cyclical vomiting that has resisted conventional treatment; or
- Post-traumatic stress disorder.
In June 2026, Kentucky also adopted an emergency regulation clarifying that certain underlying conditions may qualify when they produce a statutory qualifying symptom and are properly diagnosed or confirmed by an authorized medical cannabis practitioner. The regulation identifies conditions including amyotrophic lateral sclerosis, Parkinson’s disease, Crohn’s disease, ulcerative colitis, sickle-cell anemia, wasting syndrome, neuropathies, severe arthritis, muscular dystrophy, Huntington’s disease, HIV, AIDS, glaucoma and terminal illness. The emergency regulation on qualifying medical conditions explains the current interpretation.
How patients apply
The state’s patient and caregiver portal is open for applications. An adult Kentucky resident generally must:
- Have a qualifying medical condition;
- Visit an authorized medical cannabis practitioner in person;
- Receive a written certification stating that medical cannabis may provide a therapeutic or palliative benefit;
- Submit the required personal information and documentation through the registry; and
- Pay the $25 patient application fee and submit the required notarized signature page.
The certification must come from a practitioner authorized by Kentucky’s program. A patient’s written certification must generally be issued within 60 days before the application is submitted. Minors face additional requirements and cannot independently possess or purchase medical cannabis; a parent or legal guardian must serve as the designated caregiver.
Patients may also apply as visiting qualified patients if they hold a valid medical cannabis identification card from another state and meet Kentucky’s requirements. The state’s official patient and caregiver FAQ provides current details about documentation, fees, caregivers and card validity.
What the law permits—and what it does not
Kentucky law permits registered patients to obtain approved medical cannabis products through licensed dispensaries. The program recognizes products such as edibles, oils, tinctures, vapes and raw plant material, but patients should review the state’s restrictions carefully. For example, Kentucky prohibits smoking raw plant material and requires raw plant material packaged in the Commonwealth to carry a label stating that it is not intended for consumption by smoking. Vaping products may be purchased only by people over 21.
A Kentucky medical cannabis card also does not authorize possession or use everywhere. Restrictions apply in places such as schools, correctional facilities and other prohibited locations. Cannabis generally cannot be transported across state lines, and state authorization does not protect conduct that violates federal law.
What does the evidence show?
Cannabis and cannabinoid medicines may help with some symptoms, but the evidence varies substantially by condition and product. The National Academies of Sciences, Engineering, and Medicine found substantial evidence that cannabis or cannabinoids can improve chronic pain in adults, while evidence for other conditions is more limited or mixed.
The National Center for Complementary and Integrative Health reports that studies of chronic pain generally show a small benefit, with side effects such as dizziness and sleepiness occurring more often among people taking cannabinoid products. Evidence is stronger for some forms of neuropathic pain than for chronic pain generally. Cannabinoid medicines also have established uses for conditions such as chemotherapy-related nausea and vomiting and certain rare seizure disorders, although those treatments may involve specific prescription products rather than the broad range of products available through state cannabis programs.
Medical cannabis should not automatically be treated as a substitute for opioid therapy. High-quality human studies have produced inconsistent results on whether cannabinoids reduce opioid use, and the Centers for Disease Control and Prevention says there is limited evidence that cannabis treats most types of acute or chronic pain. The CDC also warns that cannabis use, alone or with opioids, may increase the risk of opioid misuse. Patients should discuss potential benefits, side effects, drug interactions and safer alternatives with a qualified clinician.
A regulated program with continuing questions
Kentucky’s program represents a major change in state policy, but legalization alone does not answer every medical or public-health question. Researchers still need better evidence about long-term use, product potency, dosing, interactions with other medicines and outcomes for conditions such as PTSD and chronic pain.
The program also creates a new regulated market for cultivators, processors, dispensaries and testing laboratories. Its long-term economic effects—including business activity, employment and state revenue—will depend on patient participation, supply, enforcement and how the market develops. Those outcomes should be measured rather than assumed.
For patients, the most important distinction is between state authorization and a guaranteed treatment. Kentucky now provides a legal pathway for people with qualifying conditions to seek medical cannabis under professional oversight. Whether it is appropriate remains an individual medical decision that should be based on a practitioner’s assessment and the strength of evidence for the patient’s particular condition.
